Member Info for NFTs

Perhaps 🤔 there is a reason and it will spill out soon enough!!!

The only benefit lynparza that NFX managed was to make a formula that used fractionally less powder than original. Without significant resources to continue RandD in NXP004 it’s at a standstill.

It’s been a do or die scenario here for last 2 to 3 years. The incorrect track taken was by Anne who spent the cash on rat studies to achieve a poor result on NXP002. Reason being rats are poor replication of humans but cheap and easy and what they all trained doing so struggled to understand the more positive modern human tissue testing route.

This would have achieved a positive result and left money to take NXP002 further much further to a point of early license deal.

It is what it is unfortunately for investors here and any outcome now even at this price would be a positive. Clock is ticking and a merger into a new small biotech is probably what happens with current shareholders getting stock in that company but most likely at significant discount to now. IMO

Not sure what’s worse tbh.

As of March 31st £183,000 losing around £25,000 a month so another £75,000 off that now. Therefore approx 115,000 left in the pot! Or 4/5 months till the end.

Or

These words “ continue to operate until our R&D and targeted partnering activities require further resource”

The last raise was that. The last till some other company take the going concern off their hands at mates rates ensuring certain players get a seat and stock in that entity. Mmm remember those shares allotted in Oxcillio?

Interesting that my post

“Incoming” was deleted.!!

Should see a 📬 tomorrow;)

The problem with some NED’s on boards and large influential holders in the background can cause multiple effects on a companies performance in the respect that their motives maybe not in the best interest of shareholders.

From what I am seeing here being played out is a stagnation in where the power should sit.

Is CC in charge here or are certain influences behind the BOD dictating what’s currently happening.

I would have expected now CC to have created a significant bang in the SP with the way she was peddled into position by those influential in the back.

It now comes across that those players maybe trying to grab too much control. CC now needs to turn around and remove them from the discussion table as clearly they are aiding financial companies to peddle the stock one way at moment.

This ship needs tightening up and fast.

It’s sitting on a potential TO from multiple parties and the starting gun will be fired soon.

Oh it’s coming!!!

The largest multiple to current share price for a major buying a small biotech company in the UK in recent years was **42x**. This was paid by **AstraZeneca** for **Alexion Pharmaceuticals** in 2021.

Other notable examples of high multiples paid for small biotech companies in the UK include:

* **GSK** acquired **Sierra Oncology** for **36x** its current share price in 2022.

* **Johnson & Johnson** acquired **Actelion Pharmaceuticals** for **30x** its current share price in 2017.

* **Roche** acquired **Spark Therapeutics** for **29x** its current share price in 2019.

These high multiples reflect the strong demand for promising biotech companies by large pharmaceutical companies. Biotech companies often have valuable pipelines of new drugs and technologies, which can be attractive to larger companies looking to expand their portfolios.

It is important to note that these are just a few examples, and the multiples paid for small biotech companies can vary depending on a number of factors, such as the size of the company, the stage of its development, and the potential of its pipeline.

That’s what you think 💭

How wrong assumptions can be by trying to use logic to create fact.

The problem is the logic!

Watch this space. The program the data and the general knowledge of what is growing here is very well known by BP. The irrelevant bit is PI’s assumptions of understanding what this company sits on in value to these majors.

It’s huge.

Since 19th December “Dr Simon Bennett as Chief Business Officer of the Therapeutics Division”

It’s been 5 months in position.

I can only guess that a deal is not far away imo as 6 months is general timeframe to complete.

You can see and smell the burning 🔥

You can see the desperation now as they either swallow a loss now or wait to be fully sizzled!!

Well it looks to me that the operators that create FUD to aid short selling are looking very worried here 🤣😂🤣😂🤣😂😜😎😎😎🥳🥳🥳

I think they will get burnt properly for once at last!!

NFTs

Posted in: 88E

Posts: 468

Price: 0.215

No Opinion

RE: Director Shares17 Apr 2024 08:33

Anyone worth their salt knows that they always do a presentation when building for a placing.

Wyndrum

Do you admin a telegram group by any chance ;)

Connected manipulation collusion is rife across these platforms in group attacks.

Concerted effort to try create agenda to trash SP and oust AS.

Anyone promoting this idea is either doing it to cause more damage or has no idea how stupid that idea is right now with this company on the cusp of huge negotiation period later this year.

Don’t bite the agenda these rats are spreading.

It will hurt AVACTA taking out the CEO.

CFO can be moved aS they have been silly in failing to protect us better from this nonsense.

What a pack of lies.

The level of effort is staggering.

You sold and want to buy cheaper and will continue to push negative agenda until you buy on probably a news significant day or when the trend breaks out.

Otherwise you are just as suspected a simple scamming trader playing the boards as they do to a high level.

Sad existence indeed

One simple question then!

If you are as you say not as enthusiastic as some why would you invest or stay invested if you are not that enthusiastic as PI’s we generally invest in stocks we are enthusiastic about to the extent we invest our hard earned money.

Now the the other option is you could be a trader who just buys and sells to TA or guess work but spend a lot of time trying to manipulate social media to appease yourself in doing the right thing and pathetically trying to change agenda to suit your positions.

Mmm 🤔

Wyndrum

Let’s turn your constant involvement here back on you and ask you.

What is your reason here?

Simple question.

Let’s remember the reason for holding is that they now have better results than they ever wished for.

They are cashed up so they can negotiate strongly.

They will deliver when the data of the 2 weekly studies are complete.

That the IP for much larger potential targets are being carefully put together as we speak.

That buyers are there but they do not want to negotiate any terms until the larger picture is displayed for all to see.

That lines like 3996 in early stages are worth many multiples more!!!

That even as we speak similar deals of 2bil would be on current knowledge but as the up and coming data and IP in near term this year will potentially mean deals closer to many more multiples of 2bil become likely.

These are reasons to hold onto the shares as these potentials unfold.

It’s pointless discussing with agenda ridden posts.

The facts are Dr Tap stated any improvement to standard Dox will become the future go to for Dox.

AVA6k is not only an improvement it’s blown expectations and become a potential cancer eliminating drug not just to prolong life.

It’s massively less toxic fact.

Therefore excluding the proof of Precision which again is now 100% proven.

AVA6K will become the go to for Dox chemo therapy.

The values are huge now that precision is proven to be a warhead delivery system.

What we need is to show it in the two week dosing arm to really show potentials.

You cannot argue it’s proven as they have told you it is proven.

If you cannot understand this fact then you will not listen to the fact that any FAP targeted drug will be weaponised.

The list of these drugs on and off patent is huge.

They outweigh the proof of concept drug AVA6k (Dox) by 100’s of times in 10’s of billions in annual sales.

The company that acquired Dox can out license PreCison for particular drugs on a royalty basis.

Not only can they chose but also sell the tech on many 10’s of drugs now.

It’s a race against time to lock in as much value as you can and AVACTA are not going to do that. It will always be a major.

This game starts from here and already is happening behind the scenes but before any real figure can be placed here that BP needs to say why it’s offering that price to its shareholders and BOD.

Upon which if it’s too low then a bidding war between BP will start.

I doubt anyone will get this whole entity for less then 10 bil. It’s worth that many times over on certain drugs alone.

Absolutely

You can see all the short term traders are the ones posting the frustration and nonsense across all platforms.

Ignore and watch the team deliver an outstanding result over this coming future.

Just tiresome listening to the little impatient children.

Anyone worth their salt knows that they always do a presentation when building for a placing.